AstraZeneca's Covid Vaccine Shows Potential Among HIV Patients

A new study, published in The Lancet, demonstrates that the vaccine against covid-19 from Oxford/AstraZeneca has good chances of working even among patients with HIV.

  • Fiocruz announces delivery of AstraZeneca vaccines this week
  • With 4 flights, Pfizer completes the largest delivery of covid vaccines to Brazil
  • Vaccine of Pfizer may be approved for children 5 years and older in October

The conclusion is still preliminary as the clinical trial is phase 1/2, which allows to assess the safety and immunogenicity of the vaccine, that is, its ability to induce the production of antibodies and other types of responses in the organism. The study, however, does not measure the effectiveness of the immunizing agent.

The survey was conducted in South Africa, a country known for the high prevalence of HIV in its population. Were recruited 1024 infected people and more 70 negative for the virus.

Want to catch up on the best tech news of the day? Go and subscribe to our new channel on youtube, Canaltech News.

Every day a summary of the main news in the tech world for you!

Uncontrolled HIV is one of the risk factors of covid-19 (Image: jcomp/Freepik)

The HIV-positive participants had an important requirement: they needed to be on antiretroviral therapy (ART) for at least three months, and the HIV viral load in the blood plasma should be less than 1.000 copies per microliter.

Within this study , AstraZeneca’s vaccine has been shown to be safe and well-tolerated, with no unusual and dangerous reactions, among patients with HIV. The study also demonstrated a good immunogenicity profile compared to HIV-seronegative participants.

The result will be important to understand how potent the vaccines are protectively in this population. HIV/AIDS carriers are considered a risk group for covid-19 because their natural immune response tends to be suppressed if the patient do not undergo antiretroviral treatment to control HIV.

Source: MedicalXpress

Did you like this article?

Subscribe your email on Canaltech to receive daily updates with the latest news from the world of technology.

1024 397410

397410 1024

Related Articles

Back to top button